Question 1: What is the appropriate blood pressure level? Studies have shown that the risk of coronary heart disease in people with blood pressure in the range of 115/75 to 180/115 mmHg is consistently increasing; and the risk of coronary heart disease doubles with every 20/10 mmHg increase. It is recommended that hypertensive patients with stable coronary artery disease, unstable angina, non-ST-segment elevation, and ST-segment elevation myocardial infarction should have a target blood pressure of <130/80 mmHg, but treatment should be more individualized. If the patient has occlusive coronary artery disease, diabetes mellitus, or is older than 60 years, diastolic blood pressure should be maintained above 60 mmHg. Question 2: Hypertension combined with stable angina pectoris ① Risk factor treatment: in addition to controlling blood pressure, it also includes smoking cessation, strict control of blood glucose, sports and exercise, lipid-lowering, and weight reduction in obese people. If there are no contraindications, the application of statins and antiplatelet drugs aspirin, aspirin intolerance or contraindications can be used clopidogrel; ② β-blockers: these drugs are the cornerstone of the treatment of stable coronary artery disease, and can reduce blood pressure, reduce the rate of death. Diabetes is not a contraindication to the application of β-blockers, but patients need to understand that the application of this drug may mask the symptoms of hypoglycemic adrenergic excitation; ③ other drugs: if there is a contraindication to the use of β-blockers, can be replaced by dihydropyridine calcium channel blockers, and long-term effect of the preparations (eg, amlodipine, felodipine, nifedipine controlled-release or extended-release preparations), the long-term effect of the non-dihydropyridine (e.g., amlodipine, felodipine, nifedipine controlled-release or extended-release), and long-term-acting nondihydropyridine agents (e.g., verapamil or diltiazem) are preferred and are also effective in patients with hypertension associated with angina. Most studies have shown that the combination of beta-blockers and dihydropyridine calcium channel blockers increases antianginal efficacy; however, the combination of verapamil and diltiazem may increase the risk of severe bradycardia or heart block. In addition, other drugs that can be applied include ACEI or ARB and thiazide diuretics. Question 3: Hypertension combined with unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) A comprehensive treatment program is often required for such patients, including bed rest, continuous cardiac monitoring, oxygen therapy, intravenous administration of nitrates, application of morphine, and beta-blockers or alternative medications to nondihydropyridine calcium channel blockers (e.g., verapamil, diltiazem). Both beta-blockers or non-dihydropyridine calcium channel blockers should be used in the absence of contraindications and in the absence of hypotension or heart failure. ACEIs should be added to patients with anterior wall myocardial infarction, diabetes mellitus, uncontrolled hypertension, or left ventricular systolic dysfunction. Diuretics are also necessary for prolonged blood pressure control, especially in patients with volume overload. Studies have shown that ARBs or ACEIs in patients at high cardiovascular risk (coronary artery disease, stroke, peripheral vascular disease, diabetes mellitus) can reduce the risk of cardiovascular events Issue 4: Hypertension combined with ST-segment elevation myocardial infarction The treatment of these patients is similar to that described above for unstable angina or non-ST-segment elevation myocardial infarction, although thrombolysis, direct PCI, and control of arrhythmias are more important and urgent. The treatment is more urgent. Antihypertensive drugs beta-blockers and ACEIs are indicated in all patients without contraindications. Beta-blockers can be started immediately in patients who are hemodynamically stable (no hypotension, heart failure, or cardiogenic shock) and are recommended to be administered orally. Intravenous short-acting β1-selective blockers should be considered only in patients with severe hypertension or postmyocardial infarction angina and when other medications have failed. Oral β-blockers should be continued as secondary prevention of coronary artery disease in patients beyond the acute phase. Early application of ACEI can significantly reduce morbidity and mortality, especially in patients with anterior wall myocardial infarction, persistent hypertension, left ventricular dysfunction, or diabetes mellitus. Calcium channel blockers are generally contraindicated unless the patient has a contraindication to the application of β-blockers, or with severe post-infarction angina, supraventricular tachycardia, etc., and the application of other drugs have not been effective in controlling the patient, or for the adjunctive further lowering of blood pressure.